Chiropractors in Safford, AZ Accepting Medicare

5 Chiropractors found. Showing 1 - 5

Darvil Lee Boren, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 212 W 5th St, Safford, AZ 85546 Phone: 928-428-7277

Dr. Gary Victor Scott, D.C. Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 1431 W Thatcher Blvd, Safford, AZ 85546 Phone: 928-428-0581    Fax: 928-428-0581

Family Chiropractic Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 1431 W Thatcher Blvd, Safford, AZ 85546 Phone: 928-428-0581    Fax: 928-428-0581

Jonathan D Stevens, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 520 11th Ave, Safford, AZ 85546 Phone: 928-428-1953    Fax: 928-428-1900

Darvil L Boren Dc Pc Chiropractor Medicare: Medicare Enrolled Practice Location: 212 W 5th St, Safford, AZ 85546 Phone: 928-428-7277

News Archive

Researchers define genetic landscape of uterine leiomyosarcomas

In a new study, Yale Cancer Center researchers have defined the genetic landscape of uterine leiomyosarcomas (uLMS).

Sun Pharmaceutical Industries prohibited to purchase additional Taro shares while temporary injunction remains in effect

Taro Pharmaceutical Industries Ltd. today announced that the Supreme Court of the State of Israel (the "Supreme Court") has ruled that Sun Pharmaceutical Industries Ltd. ("Sun") may not exercise a warrant to purchase additional Taro shares while a previously ordered temporary injunction remains in effect.

Study demonstrates direct link between juvenile compensatory growth and reproduction

University of California, Riverside biologists working on guppies - small freshwater fish that have been the subject of long-term studies - report that rapid growth responses to increased food availability after a period of growth restriction early in life have repercussions in adulthood.

GUMC launches phase II clinical study to examine safety of cancer drug for Parkinson's disease

Georgetown University Medical Center today announces the launch of a phase II clinical trial to study the safety of the cancer drug nilotinib and its effects on clinical outcomes and biomarkers in people with Parkinson's disease.

Read more Medical News

› Verified 9 days ago